Adaptive Trial Design
An adaptive trial design allows pre-specified modifications to the trial based on interim data—such as sample size re-estimation, stopping for futility or efficacy, dropping ineffective arms, or shifting randomization ratios toward better-performing treatments. Developed systematically in the 1990s–2000s by statisticians like Pocock and Jennison, and formalized by the FDA in 2019, adaptive designs accelerate drug development, reduce exposure to ineffective treatments, and improve efficiency without inflating false-positive rates when properly executed.
Catatan sumber
Kutipan disalin apa adanya dari catatan sumber metode. Tidak ada verifikasi tingkat klaim yang disimpulkan darinya.
- Pocock, S. J. (2005). Current issues in the design and interpretation of clinical trials. BMJ, 330(7500), 1118–1121. · URL
- Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., ... & Wason, J. (2018). Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Medicine, 16(1), 29. · DOI 10.1186/s12916-018-1017-7
- FDA (2019). Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry. US Food and Drug Administration. · URL
Klaim yang dikurasi
Klaim tersimpan dalam buku besar bukti, masing-masing dengan penilaiannya sendiri.
Tampilan ini tidak menciptakan penilaian klaim ketika buku besar tidak memilikinya.
Metode terkait
Dihasilkan dari grafik metode dan ditampilkan sebagai relasi yang disarankan mesin — tidak ada klaim bukti yang disimpulkan.